Monday , March 1 2021

Patients with fungal, gastrointestinal cancer respond well to the use of new anti-HER2 medications.

Dublin, Ireland: An antibody that binds at the same time to two different HER2 receptor regions to block the growth of cancer cells has shown promising signs of cancer activity in several cancers, including the abdomen (esophagus), the stomach and intestines.

The results of this phase of the Phase I clinical trial, called ZW25, were presented earlier this year, but updated results focusing on the esophagus, stomach, intestines and several other HER2-induced cancers were presented today. 30. EORTC-NCI-AACR Symposium on Molecular goals and cancer therapy in Dublin, Ireland.

A member of HER2, a human epidermis growth factor receptor group, best known for the role it plays in breast cancer. Trastuzumab (Herceptin) is an effective treatment for HER2-positive breast cancer. Stomach cancer driven by HER2 also responds well to trastuzumab, but if the cancer returns to these patients, HER2 target drugs have not yet been approved. Unfortunately, patients with other HER2-associated cancers currently do not have an approved HER2 target substance.

Symonet Symantec Symposium announced that as of October 16, a total of 24 patients who had received several previous treatments (median four), Dr. Murali Beer, a medical oncologist and clinical investigator at the STC Cancer Center in San Antonio, USA but whose cancer was returned, was assigned one to ten ZW25 cycles since the onset of Phase I study starting in September 2016 (either 10 mg / kg / week or 20 mg / kg every other week). All patients had HER2-positive tumors including oesophageal and gastric cancer (gastroesophageal cancer) (10 patients), intestine (5), gall bladder (3), bile duct (1), cervix (1), endometrium (1) 1) , skin (adnexal) (1) and parotid gland (1), and eight of these patients remain at the trial stage.

Recent results in 17 patients with an estimated response suggest that 13 tumors are cancerous. The median time for patients to survive without disease progression was 6.21 months. The side effects were mostly mild to moderate, with the most commonly observed diarrhea or reaction to infusion.

Dr. Beeram said, "As a clinician, I'm excited about the unique anti-cancer activity and tolerability of the drug that we see with ZW25, especially in these patents with advanced HER2-expressing cancer that developed through several previous therapies, including HER2? In fact, trastuzumab is the only HER2-targeted therapy approved for gastric cancer and no approved HER2 targeted treatment for other types of cancer administered by the HER2 receptor. The ZW25 has so far been well tolerated and allowed it to be used with other means to potentially provide even better responses. "

ZW25 is an antibody that can simultaneously link two distinct HER2 receptor regions – a protein that promotes cancer cell growth. Dr. Beer explained: "This unique design causes several mechanisms of action, including the double blockade of HER2 signals, increased binding and removal of HER2 protein from the surface of cancer cells, and stimulates the immune system to attack cancer cells, leading to antitumor activity in patients whose tumors stopped responding to approved therapies and desperately requiring new drugs that provide anticancer activity without excessive toxicity. The impressive activity of ZW25 along with its tolerance is significant and should be further explored. "

In addition to the cancer cases mentioned above, several other people also have HER2 protein; they include the uterus, ovaries, lung and bladder cancer. Zymeworks, a company that has developed the ZW25, has expanded its research and planned to conduct a Phase II / III study for patients with esophagus, stomach and other cancers next year. In addition, studies plan to study ZW25 in combination with other anticancer agents in cancer patients who have an excessive copy of the HER2 receptor and the HER2 gene, as well as those with less copies of HER2 receptors and genes.

EORTC-NCI-AACR Symposium, co-chair Professor Antoni Riba of the University of California Los Angeles, who was not involved in the research, commented: "Although these are early results in a small number of patients, they suggest that this new HER2-targeted antibody may affect cancer that is difficult to treat and which have either not been able to respond to previous therapies or are repetitive. We look forward to the results of this study, as well as future studies. "

Continue research:
Will tarloxotinib eventually stop the HER2 barrier in the lung cancer?

More information:
Abstract No .: 6, "One agent activity ZW25, HER2 targeted bispecific antibodies, HER2 expresses gastroesophageal and other cancers". Proffered papers, Plenary Sessions 2, Auditorium, at. 14.30 on Wednesday, 14 November.

ECCO is a European Canadian organization

Source link